Introduction：Basic information about CAS 18080-67-6|Conoidin A, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Conoidin A |
|---|
| CAS Number | 18080-67-6 | Molecular Weight | 347.991 |
|---|
| Density | / | Boiling Point | / |
|---|
| Molecular Formula | C10H8Br2N2O2 | Melting Point | / |
|---|
| MSDS | / | Flash Point | / |
|---|
Names
| Name | 2,3-bis(bromomethyl)-4-oxidoquinoxalin-1-ium 1-oxide |
|---|
| Synonym | More Synonyms |
|---|
Conoidin A BiologicalActivity
| Description | Conoidin A is a cell permeable inhibitor of T. gondii enzyme peroxiredoxin II (TgPrxII) with nematicidal properties. Conoidin A covalently binds to the peroxidatic Cys47 of TgPrxII, irreversibly inhibiting its hyperperoxidation activity with an IC50 of 23 µM. Conoidin A also inhibits hyperoxidation of mammalian PrxI and PrxII (but not PrxIII)[1][2]. Conoidin A has antioxidant, neuroprotective effects and can be used for the research of ischaemic heart disease[3]. |
|---|
| Related Catalog | Research Areas >>Cardiovascular DiseaseResearch Areas >>InfectionResearch Areas >>Neurological Disease |
|---|
| Target | IC50: 23 µM (T. gondii enzyme peroxiredoxin II (TgPrxII))[1] |
|---|
| In Vitro | Peroxiredoxins are a widely conserved family of enzymes that function in antioxidant defense and signal transduction. And the changes in PrxII expression are associated with a variety of human diseases, including cancer[1]. Conoidin A binds to the peroxidatic cysteine of TgPrxII, inhibiting its enzymatic activity in vitro. Conoidin A also shown to alkylate or crosslink catalytic cysteines of wild type AcePrx-1 in Ancylostoma ceylanicum and human PrxII and PrxIV with similar efficiency. But it is ineffective to mitochondrial hPrxIII[2]. Conoidin A (5 µM) can inhibit the glucose oxidase-mediated hyperoxidation of mammalian peroxiredoxin I and II[2]. |
|---|
| In Vivo | Conoidin A (intraperitoneal injection; 5 mg/kg; for three successive days before MI/R injury) blocks the effect of Luteolin (HY-N0162) on the ST‐segment elevation. Furthermore, an increase in the infarct size presented of the MI/R group can be reduced by Luteolin. But pre‐treatment with conoidin A abolishs the effect of Luteolin. Pre‐treatment with conoidin A also prevents Luteolin-reduced activities of CK‐MB, AST and LDH in vivo[3]. Animal Model: Rat myocardial I/R model[3] Dosage: 5 mg/kg Administration: Intraperitoneal injection; 5 mg/kg; for three successive days before MI/R injury Result: Significantly reversed the antioxidative effect of Luteolin. Impaired the protective effects of luteolin. |
|---|
| References | [1]. Jeralyn D Haraldsen, et al. IDENTIFICATION OF CONOIDIN A AS A COVALENT INHIBITOR OF PEROXIREDOXIN II. Org Biomol Chem. 2009;7:3040-3048. [2]. Gu Liu, et al. Optimisation of conoidin A, a peroxiredoxin inhibitor. ChemMedChem. 2010 Jan;5(1):41-5. [3]. Bo Wei, et al. Luteolin ameliorates rat myocardial ischaemia-reperfusion injury through activation of peroxiredoxin II. Br J Pharmacol |
|---|
Chemical & Physical Properties
| Molecular Formula | C10H8Br2N2O2 |
|---|
| Molecular Weight | 347.991 |
|---|
| Exact Mass | 345.895233 |
|---|
| PSA | 50.92000 |
|---|
| LogP | 3.48660 |
|---|
| InChIKey | DQKNFTLRMZOAMG-UHFFFAOYSA-N |
|---|
| SMILES | O=[n+]1c(CBr)c(CBr)n([O-])c2ccccc21 |
|---|
Safety Information
| Hazard Codes | Xi |
|---|
| HS Code | 2933990090 |
|---|
Customs
| HS Code | 2933990090 |
|---|
| Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|---|
Synonyms
| 2,3-bis(bromomethyl)quinoxaline-1,4-dioxide |
| quinoxaline, 2,3-bis(bromomethyl)-, 1,4-dioxide |
| Quinoxalinium, 2,3-bis(bromomethyl)-1,4-dihydro-4-hydroxy-1-oxo-, inner salt |
| 2,3-Bis-bromomethyl-quinoxaline 1,4-dioxide |
| 2,3-Bis(bromomethyl)-1-oxoquinoxalin-1-ium-4(1H)-olate |
| 2,3-Bis-brommethyl-chinoxalin-1,4-dioxid |
